Renaud L, Bossard JB, Carpentier B, et al. - In view of the dire outcomes of elderly or frail patients with recurrent/refractory (R/R) primary (PCNSL) and secondary CNS lymphoma (SCNSL) despite recent therapeutic advances, researchers herein retrospectively analyzed 22 immunocompetent adults with R/R PCNSL or SCNSL who received treatment with both temozolomide and ibrutinib; their median age at treatment initiation was 71 (range, 44 - 89 years). After a median of two lines of therapy (range, 1-3), all patients had relapsed (n = 6) or refractory (n = 16) disease. Data overall suggest clinical activity of temozolomide combined with ibrutinib with manageable side effects and hence it might be considered an option in these frail R/R CNS lymphomas in unmet need.